不可切除胰腺导管腺癌:CT定量成像生物标志物在预测化疗患者结局中的作用
本研究纳入41例不可切除胰腺导管腺癌患者,分析化疗前增强CT纹理参数与生存的关系。多因素Cox模型显示,肿瘤大小及SSF=3的SD、偏度和SSF=4的SD与PFS独立相关,肿瘤大小和SSF=3的SD与OS独立相关。治疗前纹理参数联合肿瘤大小在生存模型中可能优于单用影像生物标志物,但本研究未达统计学显著。
要点
- 化疗前CT纹理参数(SSF=3的SD、偏度及SSF=4的SD)与不可切除PDAC患者PFS独立相关。
- 化疗前SSF=3的SD与OS独立相关,SD≥38.38者中位OS为20.0个月,低于38.38者为9.0个月。
- 治疗后纹理参数及Δ值在多因素Cox模型中与OS或PFS均无显著关联。
核心结论
- 化疗前CT纹理分析定量成像生物标志物与接受化疗的不可切除PDAC患者的PFS和OS相关,治疗前纹理参数联合肿瘤大小在生存模型中可能优于单用影像生物标志物。
研究设计与样本
- 回顾性分析2014至2017年41例不可切除PDAC患者化疗前增强CT的肿瘤纹理,量化Mean、熵、MPP、峰度、SD和偏度(SSF 0-6),采用Cox比例风险模型和Kaplan-Meier分析评估纹理参数与生存时间的关联。
诊断标准与关键数值
- 多因素Cox模型:SSF=3的SD(HR 0.942,95%CI 0.898-0.988)、偏度(HR 0.407,95%CI 0.172-0.962)及SSF=4的SD(HR 0.958,95%CI 0.92-0.997)与PFS独立相关;SSF=3的SD(HR 0.928,95%CI 0.882-0.976)与OS独立相关;SSF=3的SD>38.38者中位PFS 10.0个月 vs ≤38.38者6.0个月(P=0.024),SSF=4的SD>40.67者中位PFS 12.0个月 vs ≤40.67者6.0个月(P=0.003);SD≥38.38(SSF=3)者中位OS 20.0个月 vs <38.38者9.0个月(P=0.04);SD联合肿瘤大小与单用SD的ROC曲线下面积分别为0.756 vs 0.715(P=0.066)。
临床应用与阅片要点
- 化疗前增强CT纹理分析所得SD和偏度可用于辅助预测不可切除PDAC患者化疗后的PFS和OS,阅片时可关注SSF=3和SSF=4的SD值。
局限性
- 治疗前SD(SSF=3)联合肿瘤大小的生存模型在本研究中未达统计学显著(ROC曲线下面积0.756 vs 0.715,P=0.066)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The primary aim of this study was to determine if computed tomographic (CT) texture analysis measurements of the tumor are independently associated with progression-free survival (PFS) and overall survival (OS) in patients with unresectable pancreatic ductal adenocarcinoma (PDAC), including both unresectable locally advanced and metastatic PDAC, who were treated with chemotherapy.
METHODS: After an institutional review board waiver was obtained, contrast material-enhanced CT studies in 41 patients with unresectable PDAC who underwent contrast-enhanced CT before chemotherapy between 2014 and 2017 were analyzed in terms of tumor texture, with quantification of mean gray-level intensity (Mean), entropy, mean of positive pixels (MPP), kurtosis, standard deviation (SD), and skewness for fine to coarse textures (spatial scaling factor (SSF) 0-6, respectively). The association between pretreatment and posttreatment texture parameters, as well as Δ value (difference between posttreatment and pretreatment texture parameters), and survival time was assessed by using Cox proportional hazards models and Kaplan-Meier analysis.
RESULTS: Findings from the multivariate Cox model indicated that tumor size, tumor SD (HR, 0.942; 95% CI: 0.898, 0.988) and skewness (HR, 0.407; 95% CI: 0.172, 0.962) measurements with SSF = 3, and tumor SD (HR, 0.958; 95% CI: 0.92, 0.997) measurements with SSF = 4 were significantly and independently associated with PFS, while tumor size and tumor SD (HR, 0.928; 95% CI: 0.882, 0.976) measurements with SSF = 3 were significantly and independently associated with OS. None of the post-therapy texture parameters or Δ value had a significant association with OS or PFS in multivariate Cox regression models. Medium SD (SSF = 3) of more than 38.38 and coarse SD (SSF = 4) of more than 40.67 were associated with longer PFS after chemotherapy (for SSF = 3, median PFS was 10.0 vs 6.0 months [P = 0.024], and for SSF = 4, median PFS was 12.0 vs 6.0 months [P = 0.003]). SD of 38.38 or greater (SSF = 3) as a dichotomized variable was a significant positive prognostic factor for OS (median OS, 20.0 vs 9.0 months [P = 0.04]). Survival models that included a combination of pretreatment SD (SSF = 3) with tumor size, had the potential to perform better than SD alone, while having no statistical significance in this study (area under the ROC curve, 0.756 vs 0.715 [P = 0.066]).
CONCLUSIONS: Pretreatment CT quantitative imaging biomarkers from texture analysis are associated with PFS and OS in patients with unresectable PDAC who were treated with chemotherapy, and the combination of pretreatment texture parameters and tumor size have the potential to perform better in survival models than imaging biomarker alone.
引用
- Cheng SH, Cheng YJ, Jin ZY, et al. Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy. Eur J Radiol. 2019. PMID: 30927946. doi:10.1016/j.ejrad.2019.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。